The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
Ontology highlight
ABSTRACT: The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors). This review will focus on ixazomib, an orally bioavailable second-generation proteasome inhibitor. Specifically, we will review the preclinical data, clinical trial experience, potential indications as well as unanswered questions pertaining to this new agent in multiple myeloma.
SUBMITTER: Brayer J
PROVIDER: S-EPMC5495505 | biostudies-other | 2017 Jul
REPOSITORIES: biostudies-other
ACCESS DATA